Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.
An 81-year-old man with longstanding ankylosing spondylitis presented to the emergency department with pain in his lower back 2 days after a fall from standing height. The pain from the injury made it ...
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease caused by the disrupted balance of both the innate immune system and acquired immune system in response to environmental factors ...
Objective Polymorphisms in the antifungal signalling molecule CARD9 are associated with ankylosing spondylitis (AS). Here, we investigated the cellular mechanism by which CARD9 controls pathogenic ...
Correspondence to Dr Pedro M Machado, Centre for Rheumatology and MRC Centre for Neuromuscular Diseases, University College London, London WC1B 5EH, UK; p.machado{at}ucl.ac.uk Contributors PMM drafted ...
It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...
GUANGZHOU, China I 7, 2025 I Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...